Enfermedad pulmonar intersticial fibrosante progresiva (EPI-FP)

 

Effect of nintedanib on FVC decline in patients with progressive fibrosing ILDs: data from the INBUILD trial

Cottin V et al.


 

Acceder

Effects of nintedanib on dyspnea, cough and quality of life in patients with progressive fibrosing interstitial lung diseases: findings from the INBUILD trial

Swigris JJ et al.
 

Acceder

Does HRCT pattern influence the effect of nintedanib in patients with progressive fibrosing interstitial lung diseases?

Brown KK et al.

 

Acceder

 

 

Effect of nintedanib in patients with progressive fibrosing interstitial lung diseases: subgroup analyses from the INBUILD trial

Kolb M et al.
 

Acceder

Safety and tolerability of nintedanib in patients with fibrosing ILDs: a comparison of the INBUILD and INPULSIS trials

Martinez FJ et al.
 

Acceder

Improving our understanding of progressive fibrosing interstitial lung diseases (ILDs): design of the ILD-PRO Registry

Palmer SM et al.
 

Acceder

 

 

Study design of a Phase III, randomized, placebo-controlled trial of nintedanib in children and adolescents with clinically significant fibrosing interstitial lung disease (ILD)

Young L et al.
 

Acceder

Identifying key considerations for early identification of interstitial lung disease: a Delphi consensus study

Hunninghake M et al.


 

Acceder

¿Te ha resultado útil esta información?